Peroxisome Proliferator-Activated Receptor β/δ: A novel target for the reduction of atherosclerosis

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 3, 2005, Pages 237-243

  Gross, Barbara S ^a   Fruchart, Jean Charles ^a   Staels, Bart ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CD36 ANTIGEN; FIBRIC ACID DERIVATIVE; GW 2433; GW 501514; GW 610742; GW 677954; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; ICOSANOID; INSULIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLX 204; PROSTACYCLIN; RETINOIC ACID; T 0913659; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNSATURATED FATTY ACID; VASCULAR CELL ADHESION MOLECULE 1; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; DYSLIPIDEMIA; ENERGY EXPENDITURE; GENE EXPRESSION REGULATION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; LIGAND BINDING; LIPID METABOLISM; LIPOGENESIS; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PREDICTION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

EID: 27144539828     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.08.009     Document Type: Review

References (39)

1. B. Desvergne and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649-688
2. H.E. Xu et al. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors Mol. Cell. 3 1999 397-403
3. N. Shaw et al. Retinoic acid is a high affinity selective ligand for the peroxisome proliferator-activated receptor β/δ J. Biol. Chem. 278 2003 41589-41592
4. B.M. Forman et al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ Proc. Natl. Acad. Sci. U S A 94 1997 4312-4317
5. G. Krey et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by co-activator-dependent receptor ligand assay Mol. Endocrinol. 11 1997 779-791
6. C. Bastie et al. Expression of peroxisome proliferator-activated receptor PPARδ promotes induction of PPARγ and adipocyte differentiation in 3T3C2 fibroblasts J. Biol. Chem. 274 1999 21920-21925
7. J.B. Hansen et al. Peroxisome proliferator-activated receptor δ (PPARδ)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling J. Biol. Chem. 276 2001 3175-3182
8. M. Westergaard et al. Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid J. Invest. Dermatol. 116 2001 702-711
9. Y. Barak et al. Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer Proc. Natl. Acad. Sci. U S A 99 2002 303-308
10. I. Saluja et al. PPARδ agonists stimulate oligodendrocyte differentiation in tissue culture Glia 33 2001 191-204
11. M.L. Sznaidman et al. Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)-synthesis and biogical activity Bioorg. Med. Chem. Lett. 11 2003 1517-1521
12. W.R. Oliver et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport Proc. Natl. Acad. Sci. U S A 98 2001 5306-5311
13. J.N. van der Veen et al. Reduced cholesterol absorption upon PPARδ activation coincides with decreased intestinal expression of NPC1L1 J. Lipid Res. 46 2005 526-534
14. H. Vosper et al. The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages J. Biol. Chem. 276 2001 44258-44265
15. M.D. Leibowitz et al. Activation of PPARδ alter lipid metabolism in db/db mice FEBS Lett. 473 2000 333-336
16. T.E. Akiyama et al. Peroxisome proliferator-activated receptor β/ δ regulates very low density lipoprotein production and catabolism in mice on a western diet J. Chem. Biol. 279 2004 20874-20881
17. C-H. Lee et al. Transcriptional repression of atherogenic inflammation: modulation by PPARδ Science 302 2003 453-457
18. A.C. Li et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ J. Clin. Invest. 114 2004 1564-1576
19. S.W. Altmann et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption Science 303 2004 1201-1204
20. H.R. Davis Jr. et al. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice Arterioscler. Thromb. Vasc. Biol. 21 2001 2032-2038
21. R.H. Knopp et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia Eur. Heart J. 24 2003 729-741
22. Y-X. Wang et al. Peroxisome proliferator-activated receptor δ activates fat metabolism to prevent obesity Cell 113 2003 159-170
23. Y-X. Wang et al. Regulation of muscle fiber type and running endurance by PPARδ Plos. Biol. 2 2004 e294
24. U. Dressel et al. The peroxisome proliferator-activated receptor β/ δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells Mol. Endocrinol. 17 2003 2477-2493
25. J.M. Wallace et al. Effects of peroxisome-activated receptor α/ δ agonists on HDL-cholesterol in vervet monkeys J. Lipid Res. 46 2005 1009-1016
26. J. Skogsberg et al. Evidence that peroxisome proliferator-activated receptor delta influences cholesterol metabolism in humans Arterioscler. Thromb. Vasc. Biol. 23 2003 637-643
27. J. Skogsberg et al. Peroxisome proliferator-activated receptor delta genotype in relation to cardiovascular risk factors and risk of coronary heart disease in hypercholesterolaemic men J. Intern. Med. 254 2003 597-604
28. D. Sprecher et al. HDLc effects in healthy subjects administered a peroxisome proliferator-activated receptor (PPAR) delta agonist Circulation 110 2004 III-52 (Abstract 244)
29. T. Tanaka et al. Activation of peroxisome proliferator-activated receptor δ induces fatty acid oxidation in skeletal muscle and attenuates metabolic syndrome Proc. Natl. Acad. Sci. U S A 100 2003 15924-15929
30. D.K. Krämer et al. Direct activation of glucose transport in primary human myotubes after activation of peroxisome proliferator-activated receptor δ Diabetes 54 2005 1157-1163
31. S. Luquet et al. Peroxisome proliferator-activated receptor δ controls muscle development and oxidative capability FASEB J. 17 2003 2299-2301
32. D.M. Muoio et al. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice J. Chem. Biol. 277 2002 26089-26097
33. D. Holst et al. Nutritional regulation and role of peroxisome proliferator-activated receptor δ in fatty acid catabolism in skeletal muscle Biochem. Biophys. Acta 1633 2003 43-50
34. H. Vosper et al. The peroxisome proliferator-activated receptor δ is required for the differentiation of THP-1 monocytic cells by phorbol ester Nucl. Recept. 1 2003 9
35. A. Chawla et al. PPARδ is a very low-density lipoprotein sensor in macrophages Proc. Natl. Acad. Sci. U S A 100 2003 1268-1273
36. Y. Rival et al. PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-kB and expression of VCAM-1 in EAhy926 endothelial cells Eur. J. Pharmacol. 435 2002 143-151
37. J.S. Welch et al. PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages Proc. Natl. Acad. Sci. U S A 100 2003 6712-6717
38. T.L. Graham et al. The PPARδ agonist GW0742X reduces atherosclerosis in LDLR-/- mice Atherosclerosis 181 2005 29-37
39. K.G. Liu et al. Identification of a series of PPARγ/δ dual agonists via solid-phase parallel synthesis Bioorg. Med. Chem. Lett. 11 2001 2959-2962